A Phase 3 interventional study of MiSight Contact Lenses (CooperVision) and Albiliti 1-Day (Johnson and Johnson, VisionCare) in Myopia Progression, sponsored by Aston University. Active, not recruiting at 1 site in New Zealand. Open to participants aged 7 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Aston University · Phase 3, Interventional, and Prevention
The study will employ a randomized, controlled, investigator-masked paired-eye comparison design to evaluate the effects of two myopia-control contact lenses-MiSight 1 Day and Abiliti 1-Day-in New Zealand Chinese children.
The study duration will be 12 months, with assessments conducted at baseline, 2 weeks, 3 months, 6 months and 12 months.
The clinical research will be conducted at the Auckland Myopia Clinic (New Zealand) and will follow a standard clinical routine for children with early myopia, the only difference being the randomizing of the MiSight and Abiliti contact lenses between the two eyes of the participants.
Participants 2.1 Recruitment and Eligibility Criteria • Participants: 53-66 New Zealand Chinese children aged 7-11 years.
Inclusion criteria:
o Spherical refractive error between -1.00D and -4.50D
o Astigmatism of ≤1.00D
o No history of orthokeratology or atropine use
o No ocular diseases or surgical history
2.2 Sample Size A similar study, of soft contact lenses with novel ring focus for controlling myopia progression, based their sample size on treatment efficacy of >0.08 mm (standard deviation [SD]: 0.10) in axial elongation from baseline and >0.20 D (SD: 0.32) in change of spherical equivalent cycloplegic autorefraction (SECAR) from baseline at 26 weeks. Controlling the 2-sided type I error rate at the 0.05 level, the researchers found that sample size of 40 subjects per group would yield >80% power for detecting treatment efficacy.
To estimate the sample size for the present study, a priori power analysis was performed using the program G∗Power (version 3.1.9.7). For a 95% confidence interval (Z = 1.96) and a study power of 80%, and controlling the 2-sided type I error rate at the 0.05 level, the estimated sample size is 53 pairs of eyes (53 subjects), as each participant contributes both eyes to the study. Providing for a 20% dropout rate, the recruitment target becomes 66 participants.
Interventions
Each participant will wear:
Data Collection Methods 4.1 Baseline and Follow-up Assessments
o Children Dry Eye Questionnaire (CDEQ) responses
o Non-invasive Tear break-up time (NIBUT) using MYAH's dry eye function
o Ocular Protection Index (OPI) calculation using MYAH
Lissamine green conjunctiva staining (graded and recorded) 4.2 Timepoints for Data Collection
1. Myopia-control efficacy: Comparison of axial length elongation between the two contact lenses.
2. Ocular surface health:
o CDEQ responses
Corneal staining severity Should one lens slow the development of myopia more than the other, the lenses will be reversed at the end of the study.
6. Parent Perception Questionnaire
A structured questionnaire will be administered at baseline and at 6 months to assess parents' expectations and perceptions of the contact lenses as a myopia treatment. Topics covered include:
Follow-up Questionnaire: Changes in attitudes, satisfaction with treatment compared to initial expectations, and future adherence.
7. Ethical Considerations The study will comply with optometric ethical standards. Participants and parents will provide informed consent. Data confidentiality will be maintained, and the study will be subject to institutional ethics review.
8. Study Personnel The study will be investigator-masked and conducted by two paediatric optometrists,who each have extensive experience in myopia management. Both have conducted over 800 paediatric myopia exams.
9. Statistical Analysis Data will be analysed using SPSS software. Axial length changes will be compared between paired eyes using paired t-tests. Dry eye symptoms and corneal staining scores will be analysed using a repeated measures ANOVA.
Aston University is the lead sponsor of 27 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
o No ocular diseases or surgical history
Commercially available myopia control contact lens
Device: MiSight Contact Lenses (CooperVision)
Commercially available myopia control contact lens
Device: Albiliti 1-Day (Johnson and Johnson, VisionCare)
Myopia Control Contact Lens
Myopia Control Contact Lens
Mean Spherical Equivalent Cycloplegic Refraction
The dioptric refractive error as determined by retinoscopy following cycloplegic refraction
Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months
Axial length
Ocular biometry measured with Myah biometer
Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months
Children Dry Eye Questionnaire (CDEQ) response
Total score derived from the Children Dry Eye Questionnaire (CDEQ)
Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months
Non-invasive Tear break-up time
Non-invasive Tear break-up time (NIBUT) using MYAH's objective dry eye function - time after a blink (in seconds) for the first break in the tear film to be detected
Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months
Ocular Protection Index
Non-invasive breakup time secondary outcome measure divided by the average blink interval (number of blinks observed in a 60s period)
Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months
Corneal punctate spots
Number of punctate spots observed on the cornea following instillation of fluorescein and illumination with a blue light source
Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months
Conjunctival punctate spots
Number of puntate spots observed over the bulbar conjunctiva following instillation of lissamine green dye
Time frame: Baseline, 2 weeks, 3 months, 6 months, 12 months
Plan to share: No — Patients have not given permission for this
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aston University